Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Supplemental material Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Roig, F. J. Articles by Amaro, C. Search for Related Content PubMed PubMed Citation Articles by Roig, F. J. Articles by Amaro, C. Agricola Articles by Roig, F. J. Articles by Amaro, C.

 Previous Article  |  Next Article 

Applied and Environmental Microbiology, April 2009, p. 2577-2580, Vol. 75, No. 8
0099-2240/09/$08.00+0     doi:10.1128/AEM.02921-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Spontaneous Quinolone Resistance in the Zoonotic Serovar of Vibrio vulnificus ^,

Francisco J. Roig, A. Llorens, B. Fouz, and C. Amaro^*

Departamento de Microbiología, Facultad de Biología, Universidad de Valencia, Valencia, Spain

Received 22 December 2008/ Accepted 4 February 2009

Top ABSTRACT INTRODUCTION REFERENCES

 
This work demonstrates that Vibrio vulnificus biotype 2, serovar E, an eel pathogen able to infect humans, can become resistant to quinolone by specific mutations in gyrA (substitution of isoleucine for serine at position 83) and to some fluoroquinolones by additional mutations in parC (substitution of lysine for serine at position 85). Thus, to avoid the selection of resistant strains that are potentially pathogenic for humans, antibiotics other than quinolones must be used to treat vibriosis on farms.

Top ABSTRACT INTRODUCTION REFERENCES

 
Vibrio vulnificus is an aquatic bacterium from warm and tropical ecosystems that causes vibriosis in humans and fish (http://www.cdc.gov/nczved/dfbmd/disease_listing/vibriov_gi.html) (33). The species is heterogeneous and has been subdivided into three biotypes and more than eight serovars (6, 15, 33; our unpublished results). While biotypes 1 and 3 are innocuous for fish, biotype 2 can infect nonimmune fish, mainly eels, by colonizing the gills, invading the bloodstream, and causing death by septicemia (23). The disease is rapidly transmitted through water and can result in significant economic losses to fish farmers. Surviving eels are immune to the disease and can act as carriers, transmitting vibriosis between farms. Interestingly, biotype 2 isolates belonging to serovar E have been isolated from human infections, suggesting that serovar E is zoonotic (2). This serovar is also the most virulent for fish and has been responsible for the closure of several farms due to massive losses of fish. A vaccine, named Vulnivaccine, has been developed from serovar E isolates and has been successfully tested in the field (14). Although the vaccine provides fish with long-term protection from vibriosis, at present its use is restricted to Spain. For this reason, in many fish farms around the world, vibriosis is treated with antibiotics, which are usually added to the food or water.

Quinolones are considered the most effective antibiotics against human and fish vibriosis (19, 21, 31). These antibiotics can persist for a long time in the environment (20), which could favor the emergence of resistant strains under selective pressure. In fact, spontaneous resistances to quinolones by chromosomal mutations have been described for some gram-negative bacteria (10, 11, 17, 24, 25, 26). Therefore, improper antibiotic treatment of eel vibriosis or inadequate residue elimination at farms could favor the emergence of human-pathogenic serovar E strains resistant to quinolones by spontaneous mutations. Thus, the main objective of the present work was to find out if the zoonotic serovar of biotype 2 can become quinolone resistant under selective pressure and determine the molecular basis of this resistance.

Very few reports on resistance to antibiotics in V. vulnificus have been published; most of them have been performed with biotype 1 isolates. For this reason, the first task of this study was to determine the antibiotic resistance patterns in a wide collection of V. vulnificus strains belonging to the three biotypes that had been isolated worldwide from different sources (see Table S1 in the supplemental material). Isolates were screened for antimicrobial susceptibility to the antibiotics listed in Table S1 in the supplemental material by the agar diffusion disk procedure of Bauer et al. (5), according to the standard guideline (9). The resistance pattern found for each isolate is shown in Table S1 in the supplemental material. Less than 14% of isolates were sensitive to all the antibiotics tested, and more than 65% were resistant to more than one antibiotic, irrespective of their biotypes or serovars. The most frequent resistances were to ampicillin-sulbactam (SAM; 65.6% of the strains) and nitrofurantoin (F; 60.8% of the strains), and the least frequent were to tetracycline (12%) and oxytetracycline (8%). In addition, 15% of the strains were resistant to nalidixic acid (NAL) and oxolinic acid (OA), and 75% of these strains came from fish farms (see Table S1 in the supplemental material). Thus, high percentages of strains of the three biotypes were shown to be resistant to one or more antibiotics, with percentages similar to those found in nonbiotyped environmental V. vulnificus isolates from Asia and North America (4, 27, 34). In those studies, resistance to antibiotics could not be related to human contamination. However, the percentage of quinolone-resistant strains found in our study is higher than that reported in other ones, probably due to the inclusion of fish farm isolates, where the majority of quinolone-resistant strains were concentrated. This fact suggests that quinolone resistance could be related to human contamination due to the improper use of these drugs in therapy against fish diseases, as has been previously suggested (18, 20). Although no specific resistance pattern was associated with particular biotypes or serovars, we found certain differences in resistance distribution, as shown in Table 1. In this respect, biotype 3 displayed the narrowest spectrum of resistances and biotype 1 the widest. The latter biotype encompassed the highest number of strains with multiresistance (see Table S1 in the supplemental material). Within biotype 2, there were differences among serovars, with quinolone resistance being restricted to the zoonotic serovar (Table 1).

View this table: [in this window] [in a new window]

TABLE 1. Percentage of resistant strains distributed by biotypes and serovars

The origin of resistance to quinolones in the zoonotic serovar was further investigated. To this end, spontaneous mutants of sensitive strains were selected from colonies growing within the inhibition halo around OA or NAL disks. Two strains (strain CG100 of biotype 1 and strain CECT 4604 of biotype 2, serovar E) developed isolated colonies within the inhibition zone. These colonies were purified, and maintenance of resistance was confirmed by serial incubations on medium without antibiotics. Using the disk diffusion method, CG100 was shown to be resistant to SAM and F and CECT 4604 to F (see Table S1 in the supplemental material). The MICs for OA, NAL, flumequine (UB), and ciprofloxacin (CIP) were determined by using the microplate assay according to the recommendations of the Clinical and Laboratory Standards Institute and the European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases (8, 12) and interpreted according to the European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases (13). The MICs for OA and NAL and for the fluoroquinolones UB and CIP exhibited by the mutants and their counterparts are shown in Table 2. The inhibition zone diameters correlated well with MICs (data not shown). Mutants FR1, FR2, FR3, and FR4 were resistant to NAL and sensitive to the remaining quinolones, although they showed higher resistances than their parental strains (Table 2). Thus, these four mutants showed increases of 32- to 128-fold for NAL MICs, 4- to 8-fold for UB MICs, and 16-fold for CIP MICs (Table 2). The fifth mutant, FR5, was resistant to the two tested quinolones and to UB, a narrow-spectrum fluoroquinolone. This mutant, although sensitive to CIP, multiplied its MIC for this drug by 128 with respect to the parental strain (Table 2).

View this table: [in this window] [in a new window]

TABLE 2. MICs for quinolones and fluoroquinolones and mutations in gyrA, gyrB, and parC detected in naturally and artificially induced resistant strains

For other gram-negative pathogens, quinolone resistance relies on spontaneous mutations in the gyrA, gyrB, parC, and parE genes that occur in a specific region of the protein known as the quinolone resistance-determining region (QRDR) (1, 11, 17, 24, 25, 26, 28). To test the hypothesis that mutations in these genes could also produce quinolone resistance in V. vulnificus, the QRDRs of these genes were sequenced in the naturally resistant strains and in the two sensitive strains that had developed resistances by selective pressure in vitro. The genomic DNA was extracted (3), and the QRDRs of gyrA, gyrB, parE, and parC were amplified using the primers shown in Table 3, which were designed from the published genomes of biotype 1 strains YJ016 and CMCP6 (7, 22). PCR products of the predicted size were sequenced in an ABI 3730 sequencer (Applied Biosystems). Analysis of the QRDR sequences for gyrA, gyrB, parC, and parE of the mutants and the naturally resistant strains revealed that all naturally resistant strains, except one, shared a specific mutation at nucleotide position 248 with the laboratory-induced mutants (Table 2). This mutation gave rise to a change from serine to isoleucine at amino acid position 83. The exception was a mutation in the adjacent nucleotide that gave rise to a substitution of arginine for serine at the same amino acid position (Table 2). All the isolates that were resistant to the quinolone NAL had a unique mutation in the gyrA gene, irrespective of whether resistance was acquired naturally or in the laboratory (Table 2). This result strongly suggests that a point mutation in gyrA that gives rise to a change in nucleotide position 83 can confer resistance to NAL in V. vulnificus biotypes 1 and 2 and that this mutation could be produced by selective pressure under natural conditions. gyrA mutations consisting of a change from serine 83 to isoleucine have also been described in isolates of Aeromonas from water (17) and in diseased fish isolates of Vibrio anguillarum (26). Similarly, replacement of serine by arginine at amino acid position 83 in diseased fish isolates of Yersinia ruckeri (16) suggests that this mechanism of quinolone resistance is widespread among gram-negative pathogens. In all cases, these single mutations were also related to increased resistance to other quinolones (OA) and fluoroquinolones (UB and CIP) (Table 2), although the mutants remained sensitive according to the standards of the Clinical and Laboratory Standards Institute and the European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases (9, 13). A total of 50% of the naturally resistant strains, all of them of biotype 1, showed additional mutations that affected parC (a change in amino acid position 113) or gyrB (changes in amino acids at positions 425 and 438) (Table 2). These strains exhibited higher MICs for OA and fluoroquinolones (Table 2), although they were still sensitive to these drugs (9, 13). Finally, one isolate of biotype 2, serovar E, which was naturally resistant to quinolones and UB, showed a mutation in parC that gave rise to a substitution of leucine for serine at amino acid position 85 (Table 2). This mutation was shared only with the laboratory-induced mutant, also a biotype 2, serovar E mutant, which was resistant to the fluoroquinolone UB. The same mutation in parC had been previously described in diseased fish isolates of V. anguillarum that were highly resistant to quinolones (28), but this had not been related to fluoroquinolone resistance in Vibrio spp. nor in other gram-negative bacteria. These results strongly suggest that resistance to fluoroquinolones in V. vulnificus is related to specific mutations in gyrA and parC and that mutations in different positions for parC or in gyrB could contribute to increased resistance to quinolones and fluoroquinolones. Our results also agree with previous studies confirming that the acquisition of higher quinolone resistance is more probable when arising from a gyrA parC double mutation than from a gyrA gyrB double mutation (29).

View this table: [in this window] [in a new window]

TABLE 3. Oligonucleotides used in this study

Finally, the evolutionary history for each protein was inferred from previously published DNA sequences of the whole genes from different Vibrio species after multiple sequence alignment with MEGA4 software (32) by applying the neighbor-joining method (30) with the Poisson correction (35). The distance tree for each whole protein showed a topology similar to the phylogenetic tree based on 16S rRNA analysis, with the two isolates of V. vulnificus forming a single group, closely related to Vibrio parahaemolyticus, Vibrio cholerae, V. anguillarum, and Vibrio harveyi (see Fig. S1A in the supplemental material). A second analysis was performed with the QRDR sequences of the different mutants and isolates of V. vulnificus (GenBank accession numbers FJ379836 to FJ379927) to infer the intraspecies relationships (see Fig. S1B in the supplemental material). This analysis showed that QRDRs of gyrA, gyrB, parC, and parE were highly homogeneous within V. vulnificus.

In summary, the zoonotic serovar of V. vulnificus can mutate spontaneously to gain quinolone resistance, under selective pressure in vitro, due to specific mutations in gyrA that involve a substitution of isoleucine for serine at amino acid position 83. This mutation appears in biotype 2, serovar E diseased-fish isolates and biotype 1 strains, mostly recovered from fish farms. An additional mutation in parC, resulting in a substitution of lysine for serine at amino acid position 85, seems to endow partial fluoroquinolone resistance on biotype 2, serovar E strains. This kind of double mutation is present in diseased-fish isolates of the zoonotic serovar but not in resistant biotype 1 isolates, which show different mutations in gyrB or in parC that increase their resistance levels but do not make the strains resistant to fluoroquinolones. Thus, antibiotics other than quinolones should be used at fish farms to prevent the emergence and spread of quinolone resistances, especially to CIP, a drug widely recommended for human vibriosis treatment.

 
This work was supported by grants AGL2008-03977/ACU and PET2005-0053 from the Ministerio de Ciencia e Innovación de España and grant MTKD-CT-2004-0145019 from the European Union.

We thank the SCSIE of the University of Valencia (Spain) for technical support and Mariola Blasco for experimental support.

 
* Corresponding author. Mailing address: Departamento de Microbiología, Facultad de Biología, Universidad de Valencia, Valencia, Spain. Phone: 00 34 96 354 31 04. Fax: 00 34 96 354 45 70. E-mail: carmen.amaro{at}uv.es

Published ahead of print on 13 February 2009.

Supplemental material for this article may be found at http://aem.asm.org/.

Top ABSTRACT INTRODUCTION REFERENCES

 

1
1. Akasaka, T., M. Tanaka, A. Yamaguchi, and K. Sato. 2001. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45:2263-2268.[Abstract/Free Full Text]
2
2. Amaro, C., and E. G. Biosca. 1996. Vibrio vulnificus biotype 2, pathogenic for eels, is also an opportunistic pathogen for humans. Appl. Environ. Microbiol. 62:1454-1457.[Abstract]
3
3. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). 2007. Current protocols in molecular biology. John Wiley & Sons, Inc., New York, NY.
4
4. Baker-Austin, C., J. McArthur, A. Lindell, M. Wright, R. Tuckfield, J. Gooch, L. Warner, J. Oliver, and R. Stepanauskas. 2008. Multi-site analysis reveals widespread antibiotic resistance in the marine pathogen Vibrio vulnificus. Microb. Ecol. doi:10.1007/s00248-008-9413-8.
5
5. Bauer, A. W., W. M. Kirby, J. C. Sherris, and M. Turck. 1966. Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol. 45:493-496.[Medline]
6
6. Bisharat, N., V. Agmon, R. Finkelstein, R. Raz, G. Ben-Dror, L. Lerner, S. Soboh, R. Colodner, D. N. Cameron, D. L. Wykstra, D. L. Swerdlow, and J. J. Farmer III. 1999. Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel. Lancet 354:1421-1424.[CrossRef][Medline]
7
7. Chen, C. Y., K. M. Wu, Y. C. Chang, C. H. Chang, H. C. Tsai, T. L. Liao, Y. M. Liu, H. J. Chen, A. B. Shen, J. C. Li, T. L. Su, C. P. Shao, C. T. Lee, L. I. Hor, and S. F. Tsai. 2003. Comparative genome analysis of Vibrio vulnificus, a marine pathogen. Genome Res. 13:2577-2587.[Abstract/Free Full Text]
8
8. Clinical and Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8th ed. Approved standard. Document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
9
9. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial disk susceptibility test, 10th ed. Approved standard. Document M02-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
10
10. Colquhoun, D. J., L. Aarflot, and C. F. Melvold. 2007. gyrA and parC mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway. Antimicrob. Agents Chemother. 51:2597-2599.[Abstract/Free Full Text]
11
11. Eaves, D. J., L. Randall, D. T. Gray, A. Buckley, M. J. Woodward, A. P. White, and L. J. Piddock. 2004. Prevalence of mutations within the quinolone resistance-determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistant Salmonella enterica. Antimicrob. Agents Chemother. 48:4012-4015.[Abstract/Free Full Text]
12
12. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 2003. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth microdilution. EUCAST discussion document E. Def 5.1. Clin. Microbiol. Infect. 9:1-7.[CrossRef][Medline]
13
13. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 2000. Determination of antimicrobial susceptibility test breakpoints. EUCAST definitive document E.DEF 2.1. Clin. Microbiol. Infect. 6:570-572.[CrossRef][Medline]
14
14. Fouz, B., M. D. Esteve-Gassent, R. Barrera, J. L. Larsen, M. E. Nielsen, and C. Amaro. 2001. Field testing of a vaccine against eel diseases caused by Vibrio vulnificus. Dis. Aquat. Organ. 45:183-189.[Medline]
15
15. Fouz, B., and C. Amaro. 2003. Isolation of a new serovar of Vibrio vulnificus pathogenic for eels cultured in freshwater farms. Aquaculture 217:677-682.[CrossRef]
16
16. Gibello, A., M. C. Porrero, M. M. Blanco, A. I. Vela, P. Liebana, M. A. Moreno, J. F. Fernandez-Garayzabal, and L. Dominguez. 2004. Analysis of the gyrA gene of clinical Yersinia ruckeri isolates with reduced susceptibility to quinolones. Appl. Environ. Microbiol. 70:599-602.[Abstract/Free Full Text]
17
17. Goñi-Urriza, M., C. Arpin, M. Capdepuy, V. Dubois, P. Caumette, and C. Quentin. 2002. Type II topoisomerase quinolone resistance-determining regions of Aeromonas caviae, A. hydrophila, and A. sobria complexes and mutations associated with quinolone resistance. Antimicrob. Agents Chemother. 46:350-359.[Abstract/Free Full Text]
18
18. Goñi-Urriza, M., M. Capdepuy, C. Arpin, N. Raymond, P. Caumette, and C. Quentin. 2000. Impact of an urban effluent on antibiotic resistance of riverine Enterobacteriaceae and Aeromonas spp. Appl. Environ. Microbiol. 66:125-132.[Abstract/Free Full Text]
19
19. Grave, K., M. K. Hansen, H. Kruse, M. Bangen, and A. B. Kristoffersen. 2008. Prescription of antimicrobial drugs in Norwegian aquaculture with an emphasis on "new" fish species. Prev. Vet. Med. 83:156-169.[CrossRef][Medline]
20
20. Halling-Sorensen, B., N. S. Nors, P. F. Lanzky, F. Ingerslev, H. C. Holten Lutzhoft, and S. E. Jorgensen. 1998. Occurrence, fate and effects of pharmaceutical substances in the environment: a review. Chemosphere 36:357-393.[CrossRef][Medline]
21
21. Kim, D. M., Y. Lym, S. J. Jang, H. Han, Y. G. Kim, C. H. Chung, and S. P. Hong. 2005. In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus. Antimicrob. Agents Chemother. 49:3489-3491.[Abstract/Free Full Text]
22
22. Kim, Y. R., S. E. Lee, C. M. Kim, S. Y. Kim, E. K. Shin, D. H. Shin, S. S. Chung, H. E. Choy, A. Progulske-Fox, J. D. Hillman, M. Handfield, and J. H. Rhee. 2003. Characterization and pathogenic significance of Vibrio vulnificus antigens preferentially expressed in septicemic patients. Infect. Immun. 71:5461-5471.[Abstract/Free Full Text]
23
23. Marco-Noales, E., M. Milan, B. Fouz, E. Sanjuan, and C. Amaro. 2001. Transmission to eels, portals of entry, and putative reservoirs of Vibrio vulnificus serovar E (biotype 2). Appl. Environ. Microbiol. 67:4717-4725.[Abstract/Free Full Text]
24
24. Mouneimne, H., J. Robert, V. Jarlier, and E. Cambau. 1999. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:62-66.[Abstract/Free Full Text]
25
25. Okuda, J., E. Hayakawa, M. Nishibuchi, and T. Nishino. 1999. Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants. Antimicrob. Agents Chemother. 43:1156-1162.[Abstract/Free Full Text]
26
26. Okuda, J., S. Kanamaru, A. Yuasa, N. Nakaoka, H. Kawakami, and T. Nakai. 2006. A possible mechanism of quinolone resistance in Vibrio anguillarum. Fish Pathol. 41:73-75.[CrossRef]
27
27. Radu, S., N. Elhadi, Z. Hassan, G. Rusul, S. Lihan, N. Fifadara, Yuherman, and E. Purwati. 1998. Characterization of Vibrio vulnificus isolated from cockles (Anadara granosa): antimicrobial resistance, plasmid profiles and random amplification of polymorphic DNA analysis. FEMS Microbiol. Lett. 165:139-143.[CrossRef][Medline]
28
28. Rodkhum, C., T. Maki, I. Hirono, and T. Aoki. 2008. gyrA and parC associated with quinolone resistance in Vibrio anguillarum. J. Fish Dis. 31:395-399.[CrossRef][Medline]
29
29. Ruiz, J. 2003. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 51:1109-1117.[Abstract/Free Full Text]
30
30. Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425.[Abstract]
31
31. Samuelsen, O. B. 1997. Efficacy of bath-administered flumequine and oxolinic acid in the treatment of vibriosis in small Atlantic halibut. J. Aquat. Anim. Health 9:127-131.[CrossRef]
32
32. Tamura, K., J. Dudley, M. Nei, and S. Kumar. 2007. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596-1599.[Abstract/Free Full Text]
33
33. Tison, D. L., M. Nishibuchi, J. D. Greenwood, and R. J. Seidler. 1982. Vibrio vulnificus biogroup 2: new biogroup pathogenic for eels. Appl. Environ. Microbiol. 44:640-646.[Abstract/Free Full Text]
34
34. Zanetti, S., T. Spanu, A. Deriu, L. Romano, L. A. Sechi, and G. Fadda. 2001. In vitro susceptibility of Vibrio spp. isolated from the environment. Int. J. Antimicrob. Agents 17:407-409.[CrossRef][Medline]
35
35. Zuckerkandl, E., and L. Pauling. 1965. Evolutionary divergence and convergence in proteins, p. 97-166. In V. Bryson and H. J. Vogel (ed.), Evolving genes and proteins. Academic Press, New York, NY.

---

Applied and Environmental Microbiology, April 2009, p. 2577-2580, Vol. 75, No. 8
0099-2240/09/$08.00+0     doi:10.1128/AEM.02921-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

This Article Abstract Full Text (PDF) Supplemental material Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Roig, F. J. Articles by Amaro, C. Search for Related Content PubMed PubMed Citation Articles by Roig, F. J. Articles by Amaro, C. Agricola Articles by Roig, F. J. Articles by Amaro, C.